Physician profile
Pamela Wright
NPI 1164739751
$2,673.82
in general payments reported to CMS, 2019-2025
31 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $464 · 2023: $551 · 2024: $364 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.75 | 2021-2025 | |
| Novo Nordisk INC | $346.62 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Genzyme Corporation | $174.54 | 2024-2025 | |
| Pfizer INC. | $172.65 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $135.58 | 2021-2022 | |
| Amgen INC. | $131.76 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $108.69 | 2021-2025 | Fasenra, Farxiga, Tezspire |
| Novartis Pharmaceuticals Corporation | $89.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.19 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.71 | 2021-2023 | Nucala |
| Mylan Specialty L.P. | $57.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.63 | 2023-2025 | Xifaxan |
| Biogen, INC. | $49.51 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.37 | 2021-2023 | Rexulti |
| Abbott Laboratories | $33.77 | 2021-2023 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.34 | 2022-2025 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $30.98 | 2024-2025 | Eliquis |
| Xeris Pharmaceuticals, INC. | $30.89 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.84 | 2024-2025 | Austedo Xr, Ajovy |
| Dexcom, INC. | $28.55 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $20.63 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.39 | 2021 | |
| Amarin Pharma, INC. | $16.87 | 2021 | |
| Medtronic, INC. | $15.93 | 2025 | Synchromedii |
| Meridian Bioscience INC. | $14.90 | 2023 | |
| Merck Sharp & Dohme LLC | $14.64 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.25 | 2023 | Quviviq |
| Eisai INC. | $14.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.92 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $13.86 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.